|
|
Post by mnholdem on Oct 14, 2019 14:03:04 GMT -5
I used to think that about short-term intensive insulin treatment for early Type 2 diabets. ~ 50% drug free remission, multiple studies involving thousands of trial participants and STII still barely gets a mention in the Standard of Care and remains the last choice for treatment.
|
|
|
|
Post by mnholdem on Oct 14, 2019 12:44:29 GMT -5
In all fairness to MannKind management:
Information provided by (Responsible Party):
Diabetes and Glandular Disease Clinic
 |
|
|
|
Post by mnholdem on Oct 14, 2019 12:41:59 GMT -5
I used to say this a lot: "The science will prevail." Good fortune! |
|
|
|
Post by mnholdem on Oct 14, 2019 11:48:03 GMT -5
|
|
|
|
Post by mnholdem on Oct 14, 2019 11:18:48 GMT -5
clinicaltrials.gov/ct2/show/NCT04125082?term=mannkind&recrs=abf&rank=3Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Site, Investigator-Initiated Study to Evaluate Time in Range in Subjects With Type 2 Diabetes Mellitus Using Mealtime Inhaled Insulin (Afrezza®) Plus Basal Insulin Compared to Multiple Daily Injections
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : March 1, 2020Recruitment Status : Recruiting First Posted : October 14, 2019 Last Update Posted : October 14, 2019 It would appear that the Estimated Primary Completion Date is only a few weeks away. If the Actual Study Start Date was in February, why would MannKind wait until October 14 to make its first post with ClinicalTrials.gov? This management team is strange...
|
|
|
|
Post by mnholdem on Oct 13, 2019 7:05:17 GMT -5
Michael Castagna was MannKind's Chief Commercial Officer at the time wasn't he?
|
|
|
|
Post by mnholdem on Oct 9, 2019 7:37:16 GMT -5
I think the term “going nuclear” was not mine but came from vdexdiabetes response to my suggestion of using localized media coverage.
|
|
|
|
Post by mnholdem on Oct 8, 2019 20:38:09 GMT -5
Example: An investment firm has orders to buy somewhere within the spread. They have the buying power to purchase shares at the low end of the spread and fill their customers’ orders at a higher price, pocketing a percentage of the spread.
|
|
|
|
Post by mnholdem on Oct 8, 2019 20:22:33 GMT -5
I highly doubt that commission-free trades will last more than a year. However, TD Ameritrade is still charging a fee per option, even though it’s a bit less.
|
|
|
|
Post by mnholdem on Oct 8, 2019 20:19:46 GMT -5
Isn’t STAT the new home of Adam Feuerstein? Thank goodness they have more than one staff writer!
|
|
|
|
Post by mnholdem on Oct 8, 2019 13:58:46 GMT -5
There's really no way for me to know that or not but all evidence available to the public tends to support your statement. The job is not only to delegate but to set timelines and HOLD ACCOUNTABLE those you've delegated tasks to. As I've posted before, company goals must be set very low for management to have qualified to receive bonus compensation over the pasts several years. |
|
|
|
Post by mnholdem on Oct 8, 2019 13:04:39 GMT -5
"Afrezza is expected to arrive in Brazil by 2020, making it the second country to receive it." 2020? I thought it was q4 2019? Castagna probably is concerned about making the same error as last year, when he stated that he thought Afrezza would be approved in Brazil by 4Q18. Instead, it took until June 2019. |
|
|
|
Post by mnholdem on Oct 8, 2019 13:02:05 GMT -5
All true. My point is that "lack of funds" should not be a hindrance anymore to moving some of the pipeline API into Phase 1 clinicals. I would have thought that MannKind would have been meeting with the FDA by now but, if history is any indication, management doesn't appear to engage much in concurrent engineering.
IMO, the CEO should be coordinating his management team on multiple fronts and shortening the timeline by holding them accountable for ensuring that multiple activities are happening at the same time in areas other than financing, investment conferences and Afrezza. Coordinating with the FDA for Phase 1 trial protoclas should have been completed long ago for most of the API.
|
|
|
|
Post by mnholdem on Oct 8, 2019 12:15:01 GMT -5
Castagna also spent some time two conferences ago talking about the low cost of Phase 1 trials. Was he indicating some movement within the pipeline or blowing smoke? Inquiring minds want to know..,
|
|
|
|
Post by mnholdem on Oct 7, 2019 19:23:05 GMT -5
So we’ll let those opinions stand. Repeatedly. And since nobody can contribute any information of substance, I’m locking this hijacked thread. If new, verified information becomes available it will be reopened.
|
|
